LAIKNA-B (02105) surged nearly 7% against the broader market trend. At the time of writing, the stock was up 2.88%, trading at HK$19 with a turnover of HK$27.711 million.
The company announced via its official WeChat account that on November 12, it granted Qilu Pharmaceutical the exclusive rights to research, develop, and commercialize the breast cancer drug candidate LAE002 (afuresertib) in China. Under the licensing agreement, LAIKNA could receive up to RMB 2.045 billion in upfront and milestone payments, along with tiered royalties ranging from 10% to 20% based on net sales.
Additionally, the Phase III clinical trial for LAE002 targeting HR+/HER2- breast cancer is expected to complete patient enrollment by Q4 2025, with a New Drug Application (NDA) submission planned for 2026.
The collaboration between LAIKNA and Qilu optimizes R&D and commercial resource allocation, reflecting the increasing specialization in China's pharmaceutical industry. This partnership exemplifies complementary resource matching among different types of enterprises, marking a breakthrough against internal competition and homogenization.
LAE002 serves as just the beginning, demonstrating LAIKNA's BD capabilities, clinical execution, and financial strength while reinforcing its core strategy of muscle gain and fat loss. The weight-loss drug market is being redefined, with preserving or even increasing lean muscle mass emerging as a key goal for next-generation therapies. Combination treatments, muscle protection, formulation innovations, and mechanism expansion will become critical competitive areas in the future.
Comments